Matthew K Moore, Gregory T Jones, Gillian Whalley, Michael Ja Williams, Ralph A Stewart, Sean Coffey
{"title":"与新西兰欧洲人相比,Māori接受临床指示超声心动图的主动脉瓣狭窄患病率。","authors":"Matthew K Moore, Gregory T Jones, Gillian Whalley, Michael Ja Williams, Ralph A Stewart, Sean Coffey","doi":"10.26635/6965.6621","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>There are limited data on the prevalence of calcific aortic valve disease (CAVD) in Māori and known inequities in outcomes after aortic valve intervention. Our study aimed to investigate the prevalence of CAVD in Māori.</p><p><strong>Methods: </strong>Data from initial clinically indicated echocardiograms performed between 2010 to 2018 in patients aged ≥18 years were linked to nationally collected outcome data. Ethnicity was defined using protocols from the Ministry of Health.</p><p><strong>Results: </strong>Of the 23,635 patients, 1,312 (5.6%) identified as Māori, and 22,323 (94.4%) as European. Prevalence of aortic stenosis was 5.3% in Māori and 9.9% in Europeans. Age-specific prevalence did not differ between the two groups. Māori with CAVD were more than twice as likely to have advanced cardiac impairment (right ventricular dysfunction) than Europeans (10.1% vs 4.6, p<0.001).</p><p><strong>Conclusions: </strong>Age-specific CAVD rates did not differ between Māori and Europeans, though Māori had a higher proportion of advanced cardiac impairment, which is likely unrelated to CAVD. Differences in population structure likely explain the difference in overall prevalence of CAVD. The improving life expectancy in Māori may lead to increasing incidence of CAVD, thus strategies to improve detection and medical management of CAVD should begin as soon as possible.</p>","PeriodicalId":48086,"journal":{"name":"NEW ZEALAND MEDICAL JOURNAL","volume":"138 1608","pages":"84-93"},"PeriodicalIF":1.2000,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The prevalence of aortic stenosis in Māori undergoing clinically indicated echocardiography compared to New Zealand Europeans.\",\"authors\":\"Matthew K Moore, Gregory T Jones, Gillian Whalley, Michael Ja Williams, Ralph A Stewart, Sean Coffey\",\"doi\":\"10.26635/6965.6621\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>There are limited data on the prevalence of calcific aortic valve disease (CAVD) in Māori and known inequities in outcomes after aortic valve intervention. Our study aimed to investigate the prevalence of CAVD in Māori.</p><p><strong>Methods: </strong>Data from initial clinically indicated echocardiograms performed between 2010 to 2018 in patients aged ≥18 years were linked to nationally collected outcome data. Ethnicity was defined using protocols from the Ministry of Health.</p><p><strong>Results: </strong>Of the 23,635 patients, 1,312 (5.6%) identified as Māori, and 22,323 (94.4%) as European. Prevalence of aortic stenosis was 5.3% in Māori and 9.9% in Europeans. Age-specific prevalence did not differ between the two groups. Māori with CAVD were more than twice as likely to have advanced cardiac impairment (right ventricular dysfunction) than Europeans (10.1% vs 4.6, p<0.001).</p><p><strong>Conclusions: </strong>Age-specific CAVD rates did not differ between Māori and Europeans, though Māori had a higher proportion of advanced cardiac impairment, which is likely unrelated to CAVD. Differences in population structure likely explain the difference in overall prevalence of CAVD. The improving life expectancy in Māori may lead to increasing incidence of CAVD, thus strategies to improve detection and medical management of CAVD should begin as soon as possible.</p>\",\"PeriodicalId\":48086,\"journal\":{\"name\":\"NEW ZEALAND MEDICAL JOURNAL\",\"volume\":\"138 1608\",\"pages\":\"84-93\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2025-01-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"NEW ZEALAND MEDICAL JOURNAL\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.26635/6965.6621\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"NEW ZEALAND MEDICAL JOURNAL","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26635/6965.6621","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
摘要
目的:关于Māori中钙化性主动脉瓣疾病(CAVD)患病率的数据有限,主动脉瓣干预后的结果也存在已知的不公平。我们的研究旨在调查Māori的CAVD患病率。方法:将2010年至2018年年龄≥18岁患者的初始临床适应症超声心动图数据与全国收集的结果数据相关联。种族是根据卫生部的规程确定的。结果:在23635例患者中,1312例(5.6%)确定为Māori, 22323例(94.4%)为欧洲患者。主动脉瓣狭窄的患病率在Māori为5.3%,在欧洲为9.9%。两组之间的年龄特异性患病率没有差异。Māori与CAVD患者发生晚期心脏损害(右室功能障碍)的可能性是欧洲人的两倍多(10.1% vs 4.6)。结论:年龄特异性CAVD发生率在Māori和欧洲人之间没有差异,尽管Māori患者发生晚期心脏损害的比例更高,这可能与CAVD无关。人群结构的差异可能解释了CAVD总体患病率的差异。Māori预期寿命的提高可能导致CAVD发病率的增加,因此应该尽快开始改进CAVD的检测和医疗管理的策略。
The prevalence of aortic stenosis in Māori undergoing clinically indicated echocardiography compared to New Zealand Europeans.
Aim: There are limited data on the prevalence of calcific aortic valve disease (CAVD) in Māori and known inequities in outcomes after aortic valve intervention. Our study aimed to investigate the prevalence of CAVD in Māori.
Methods: Data from initial clinically indicated echocardiograms performed between 2010 to 2018 in patients aged ≥18 years were linked to nationally collected outcome data. Ethnicity was defined using protocols from the Ministry of Health.
Results: Of the 23,635 patients, 1,312 (5.6%) identified as Māori, and 22,323 (94.4%) as European. Prevalence of aortic stenosis was 5.3% in Māori and 9.9% in Europeans. Age-specific prevalence did not differ between the two groups. Māori with CAVD were more than twice as likely to have advanced cardiac impairment (right ventricular dysfunction) than Europeans (10.1% vs 4.6, p<0.001).
Conclusions: Age-specific CAVD rates did not differ between Māori and Europeans, though Māori had a higher proportion of advanced cardiac impairment, which is likely unrelated to CAVD. Differences in population structure likely explain the difference in overall prevalence of CAVD. The improving life expectancy in Māori may lead to increasing incidence of CAVD, thus strategies to improve detection and medical management of CAVD should begin as soon as possible.